Can a targeted pill boost lung cancer treatment?
NCT ID NCT07777822
First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time
Summary
This phase 3 trial is investigating whether adding an investigational drug called zoldonrasib to standard first-line treatment (pembrolizumab plus chemotherapy) can help people with metastatic non-squamous non-small cell lung cancer that has a specific genetic mutation (RAS G12D). Participants will be randomly assigned to receive either the new drug combination or a placebo with the standard treatment. The study aims to see if the addition of zoldonrasib improves how long people live without their cancer progressing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zoldonrasib (an investigational RAS(ON) inhibitor) combined with pembrolizumab and platinum-based chemotherapy
- What this could lead to
- If successful, this could lead to a new first-line treatment option for people with metastatic non-squamous NSCLC carrying the RAS G12D mutation, potentially extending the time before the cancer progresses.
- What could go wrong
- This is an early-stage test in a specific patient group, and the drug may not improve outcomes or could cause additional side effects. Results are not yet available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Florida Clinical Trials Group, LLC
RECRUITINGPlantation, Florida, 33322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Direct-to-Brain chemo route outsmart resistant lung cancer?
- Electric pulses could zap lung tumors without surgery
- Can a drug duo shrink inoperable lung tumors enough for surgery?
- Can a precise Lung-Sparing surgery beat standard lobectomy for early lung cancer?
- Can lattice radiation boost immunotherapy to shrink lung tumors before surgery?
- Can fewer radiation sessions be safer for lung cancer?